# PCOS and GLP-1 medications: what the research shows

Canonical page: https://bodienvi.com/blog/pcos-and-glp1-medications

Published November 5, 2026. Updated November 5, 2026. By Bodi Envi Clinical Content Team.

What polycystic ovary syndrome has to do with insulin and weight, what studies of GLP-1 medications in PCOS found so far, and what to ask your provider.

## What PCOS is

Polycystic ovary syndrome, or PCOS, is a hormone condition. The Office on Women's Health explains that people with PCOS often have higher than normal levels of androgens, hormones that can stop the ovaries from releasing an egg each cycle and can cause extra hair growth and acne. Signs can include irregular or missed periods, hair growth on the face or body, acne, thinning scalp hair, darkened skin along the neck or under the breasts, and weight gain or difficulty losing weight. The exact cause is not known, and experts think several factors, including genetics, play a role.

## Why insulin is part of the picture

Insulin is the hormone that helps your body use the glucose from food. Insulin resistance means your cells do not respond to it normally, so insulin levels in the blood rise. The Office on Women's Health says many women with PCOS have insulin resistance, especially those who have overweight or obesity, have a family history of type 2 diabetes, or are not physically active. It also reports that more than half of women with PCOS will have diabetes or prediabetes before age 40.

That link is the reason PCOS comes up so often in conversations about GLP-1 medications. These medications act on the hormones that regulate appetite and blood sugar after meals.

## Are GLP-1 medications approved for PCOS?

No. Wegovy® (semaglutide) and Zepbound® (tirzepatide) are FDA approved, with a reduced calorie diet and more physical activity, to reduce excess body weight and keep it off in adults with obesity, or with overweight and at least one weight related health condition. Neither label lists PCOS as an indication. Metformin, a diabetes medicine often used in PCOS, is not FDA approved for PCOS either, according to the Office on Women's Health. A provider who prescribes treatment to someone with PCOS is treating weight or blood sugar, and PCOS is part of their overall health picture.

## What studies have found so far

The research on GLP-1 medications in PCOS is growing but still small, and the findings are cautious.

A 2024 review written to inform the international PCOS guideline found that liraglutide and semaglutide appeared better than placebo for body measurements, but concluded that published data in women with PCOS are very limited and called for more research.

A 2026 review of 11 randomized trials in the European Journal of Endocrinology found that adding a GLP-1 medication was associated with modest short term weight reduction in women with PCOS and overweight or obesity. It found the evidence was not strong enough to draw conclusions about blood sugar, insulin, unwanted hair growth or cycle regularity, and that no trial had measured quality of life or mental health.

A 2025 randomized trial of 100 women with PCOS and overweight or obesity compared metformin alone with metformin plus weekly semaglutide for 16 weeks. The combination group had greater reductions in weight and waist to hip ratio, larger improvements in testosterone, and higher rates of menstrual cycle recovery than the metformin group.

This pertains to the brand name only. You cannot compare the personalized compounded version to this study because it is a different product entirely. For personalized compounds, the medical provider should be consulted.

## Cycles, fertility and pregnancy planning

A 2026 review of three randomized trials, with 252 participants in total, found a higher rate of natural pregnancy with GLP-1 based treatment than with metformin alone, but no clear difference in overall pregnancy. The authors called the evidence promising but limited.

That matters for safety. If your cycles become more regular, you may be more likely to become pregnant, and these medications are not for use in pregnancy. The Wegovy® label says to stop it at least 2 months before a planned pregnancy because semaglutide stays in the body for a long time. The Zepbound® label says it may cause fetal harm and should be stopped when pregnancy is recognized. The Zepbound® label also says tirzepatide may make birth control pills less effective, and advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose increase.

This pertains to the brand name only. You cannot compare the personalized compounded version to this study because it is a different product entirely. For personalized compounds, the medical provider should be consulted.

If you are trying to conceive, or might be, tell your provider before you start. Your provider decides whether treatment fits and when to stop it.

## What this means for a compounded prescription

Every study above used brand name or study medications, and personalized compounded semaglutide and tirzepatide are not FDA-approved and were not studied in those trials.

Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.

At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.

Whatever you take, share your PCOS diagnosis, any medicines you take for it, and your pregnancy plans with your provider. Dosing, stopping and switching are always your provider's decision.

## Frequently asked questions

### Can a GLP-1 medication cure PCOS?

No. There is no cure for PCOS, and no GLP-1 medication is FDA approved to treat it. Studies so far show modest short term weight reduction in women with PCOS, with less certainty about hormones, cycles and other symptoms. This pertains to the brand name only. You cannot compare the personalized compounded version to this study because it is a different product entirely. For personalized compounds, the medical provider should be consulted. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.

### Will my periods become regular?

One 2025 trial found higher rates of menstrual cycle recovery with semaglutide plus metformin than with metformin alone, and a 2026 review found the evidence on cycle regularity was not yet strong enough to draw conclusions. No study can tell you how your own body will respond. This pertains to the brand name only. You cannot compare the personalized compounded version to this study because it is a different product entirely. For personalized compounds, the medical provider should be consulted. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.

### Can I take a GLP-1 medication with metformin?

Several PCOS trials studied the two together. Whether the combination is right for you depends on your health and your other medicines, and that is your provider's decision. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.

### Do I need to change my birth control?

If you take birth control pills, the Zepbound® label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. Ask your provider how this applies to your prescription. This pertains to the brand name only. You cannot compare the personalized compounded version to this study because it is a different product entirely. For personalized compounds, the medical provider should be consulted. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.

### Does weight loss itself help PCOS?

The Office on Women's Health says that losing weight may help lower blood glucose, improve the way your body uses insulin and help hormones reach normal levels, and that even a 10% loss in body weight can help make cycles more regular. Healthy eating and regular activity are part of that, with or without medication. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.

## Sources

- Office on Women's Health, Polycystic ovary syndrome: https://womenshealth.gov/a-z-topics/polycystic-ovary-syndrome (checked November 2026)
- NICHD, About Polycystic Ovary Syndrome (PCOS): https://www.nichd.nih.gov/health/topics/pcos/conditioninfo (checked November 2026)
- Wegovy® (semaglutide) prescribing information, sections 1, 8.1 and 8.3, DailyMed, Revised 6/2026: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b (checked November 2026)
- Zepbound® (tirzepatide) prescribing information, sections 1, 7.2, 8.1 and 8.3, DailyMed, Revised 8/2026: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b (checked November 2026)
- Anti-obesity pharmacological agents for polycystic ovary syndrome, Obesity Reviews, 2024: https://doi.org/10.1111/obr.13704 (checked November 2026)
- GLP-1 receptor agonist treatment in women with polycystic ovary syndrome, a systematic review and meta-analysis, European Journal of Endocrinology, 2026: https://doi.org/10.1093/ejendo/lvag033 (checked November 2026)
- Combined metformin and semaglutide therapy in overweight or obese women with PCOS, a randomized controlled trial, Reproductive Biology and Endocrinology, 2025: https://doi.org/10.1186/s12958-025-01447-3 (checked November 2026)
- GLP-1 receptor agonists versus metformin on pregnancy rates in women with PCOS, European Journal of Obstetrics, Gynecology, and Reproductive Biology, 2026: https://doi.org/10.1016/j.ejogrb.2026.115499 (checked November 2026)
